BR9914568A - Formulação aquosa de insulina, preparação de insulina e método de tratamento de diabetes do tipo i ou do tipo ii - Google Patents

Formulação aquosa de insulina, preparação de insulina e método de tratamento de diabetes do tipo i ou do tipo ii

Info

Publication number
BR9914568A
BR9914568A BR9914568-5A BR9914568A BR9914568A BR 9914568 A BR9914568 A BR 9914568A BR 9914568 A BR9914568 A BR 9914568A BR 9914568 A BR9914568 A BR 9914568A
Authority
BR
Brazil
Prior art keywords
insulin
type
formulation
diabetes
aqueous formulation
Prior art date
Application number
BR9914568-5A
Other languages
English (en)
Inventor
Svend Havelund
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of BR9914568A publication Critical patent/BR9914568A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"FORMULAçãO AQUOSA DE INSULINA, PREPARAçãO DE INSULINA E MéTODO DE TRATAMENTO DE DIABETES DO TIPO I OU DO TIPO II". é apresentada uma formulação de insulina estável, aquosa, adequada para aporte pulmonar. A formulação é composta de insulina ou um análogo da mesma, 2 a 5 íons de Zn^ 2+^ por 6 moléculas de insulina, 3 a 18 moléculas fenólicas por 6 moléculas de insulina, e mentol. O cheiro característico de mentol mascara a presença de fenóis na formulação sem afetar a estabilidade química e física da formulação.
BR9914568-5A 1998-10-16 1999-10-15 Formulação aquosa de insulina, preparação de insulina e método de tratamento de diabetes do tipo i ou do tipo ii BR9914568A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA199801326 1998-10-16
PCT/DK1999/000557 WO2000023099A1 (en) 1998-10-16 1999-10-15 Insulin preparations for pulmonary delivery containing menthol

Publications (1)

Publication Number Publication Date
BR9914568A true BR9914568A (pt) 2001-07-03

Family

ID=8103609

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9914568-5A BR9914568A (pt) 1998-10-16 1999-10-15 Formulação aquosa de insulina, preparação de insulina e método de tratamento de diabetes do tipo i ou do tipo ii

Country Status (20)

Country Link
EP (1) EP1121145B1 (pt)
JP (1) JP2002527488A (pt)
KR (1) KR20010080132A (pt)
CN (1) CN1323220A (pt)
AT (1) ATE216258T1 (pt)
AU (1) AU758108B2 (pt)
BR (1) BR9914568A (pt)
CA (1) CA2346884A1 (pt)
CZ (1) CZ20011133A3 (pt)
DE (1) DE69901314T2 (pt)
DK (1) DK1121145T3 (pt)
ES (1) ES2177324T3 (pt)
HU (1) HUP0103606A3 (pt)
IL (1) IL142002A0 (pt)
NO (1) NO20011841L (pt)
PL (1) PL347171A1 (pt)
PT (1) PT1121145E (pt)
UA (1) UA67798C2 (pt)
WO (1) WO2000023099A1 (pt)
ZA (1) ZA200102068B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7089053B1 (en) 1999-10-14 2006-08-08 Pola Chemical Industries Inc Compositions for drug administration by electroporation
ATE328581T1 (de) * 1999-10-15 2006-06-15 Pola Chem Ind Inc Perkutane absorptionsbeschleuniger für die elektroporation
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
CN102256618A (zh) 2008-10-17 2011-11-23 赛诺菲-安万特德国有限公司 胰岛素和glp-1激动剂的组合
PL2451437T3 (pl) 2009-07-06 2017-05-31 Sanofi-Aventis Deutschland Gmbh Wodne preparaty insuliny zawierające metioninę
TR201809460T4 (tr) 2009-11-13 2018-07-23 Sanofi Aventis Deutschland Bir GLP- 1-agonisti, bir insülin ve metiyonin içeren farmasötik bileşim.
NZ599847A (en) 2009-11-13 2013-09-27 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
WO2012028172A1 (en) 2010-08-30 2012-03-08 Sanofi-Aventis Deutschland Gmbh Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
AR087693A1 (es) 2011-08-29 2014-04-09 Sanofi Aventis Deutschland Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
PE20171622A1 (es) 2014-12-12 2017-11-02 Sanofi Aventis Deutschland Formulacion de relacion fija de insulina glargina/lixisenatida
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
GB201906917D0 (en) * 2019-05-16 2019-07-03 Intract Pharma Ltd Novel compositions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506203C1 (en) * 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
US5504188A (en) * 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5635161A (en) * 1995-06-07 1997-06-03 Abbott Laboratories Aerosol drug formulations containing vegetable oils
PL188736B1 (pl) * 1996-06-20 2005-04-29 Novo Nordisk As Wodny preparat insuliny oraz sposób jego przygotowania
ATE219942T1 (de) * 1997-03-20 2002-07-15 Novo Nordisk As Therapeutische pulverformulierung zur pulmonaren anwendung, welche kristallines insulin enthält

Also Published As

Publication number Publication date
JP2002527488A (ja) 2002-08-27
NO20011841D0 (no) 2001-04-10
DE69901314T2 (de) 2002-11-21
CN1323220A (zh) 2001-11-21
NO20011841L (no) 2001-06-15
CZ20011133A3 (cs) 2001-08-15
WO2000023099A1 (en) 2000-04-27
AU6189099A (en) 2000-05-08
HUP0103606A2 (hu) 2002-02-28
AU758108B2 (en) 2003-03-13
ZA200102068B (en) 2001-10-12
HUP0103606A3 (en) 2002-05-28
EP1121145B1 (en) 2002-04-17
DE69901314D1 (de) 2002-05-23
KR20010080132A (ko) 2001-08-22
PL347171A1 (en) 2002-03-25
IL142002A0 (en) 2002-03-10
PT1121145E (pt) 2002-09-30
ATE216258T1 (de) 2002-05-15
EP1121145A1 (en) 2001-08-08
DK1121145T3 (da) 2002-08-12
CA2346884A1 (en) 2000-04-27
ES2177324T3 (es) 2002-12-01
UA67798C2 (uk) 2004-07-15

Similar Documents

Publication Publication Date Title
BR9914568A (pt) Formulação aquosa de insulina, preparação de insulina e método de tratamento de diabetes do tipo i ou do tipo ii
BR9914585A (pt) Formulação aquosa de insulina, preparação de insulina, e, método de tratamento de diabetes do tipo i ou do tipo ii
BR9811249A (pt) Nova formulação para inalação; apresentando densidade volumétrica, quando derramada, de 0,20 à 0,38g/ml, processo para preparação de formulação e uso da mesma
CO4410203A1 (es) Formulaciones de analogos de insulina
CO5271759A1 (es) Formulacion en solucion que contiene una mezcla de disolventes
BR0116169A (pt) Composto, composição farmacêutica que compreende esse composto, processo para a preparação de uma composição farmacêutica, utilização dos compostos, processo para o tratamento profilático ou terapêutico de diabetes do tipo ii e processo para a preparação do composto.
BR9715022A (pt) Método para tratar de doenças prostáticas usando formulações de vitamina d por liberação sistemática e/ou prolongada
BR9914507A (pt) Concentrado de substância ativa com formoterol, adequado para armazenagem
D’Agostini et al. Chemoprevention of smoke-induced alopecia in mice by oral administration of L-cystine and vitamin B6
BR9809283A (pt) Inalador para se administrar medicamento por inalação, e, processo de fabricação de um alojador de um inalador para se administrar medicamento por meio de inalação.
Morris Uptake of acetaldehyde vapor and aldehyde dehydrogenase levels in the upper respiratory tracts of the mouse, rat, hamster, and guinea pig
BR9814855A (pt) Processo para tratamento antimicrobiano de microrganismos e/ou vìrus, e, composição antimicrobiana.
BR9805586A (pt) Composições em pó.
SE7612534L (sv) Forfarande for framstellning av farmaceutiska preparat for behandling av storningar i kalciumemnesomsettning
DE69916695D1 (de) Verwendung mindestens eines Hydroxystilbene als Mittel zur Verringerung der Adhäsion von Mikroorganismen
He et al. Application of Direct Analysis in Real Time–High Resolution Mass Spectrometry to Investigations of Induced Plant Chemical Defense Mechanisms—Revelation of Negative Feedback Inhibition of an Alliinase
BR9909478A (pt) Novos tratamentos para vários distúrbios do sistema nervoso
BR9912578A (pt) Composição para refrescar as narinas e as cavidades dos seios nasais.
DE69811758D1 (de) Verwendung von Hyaluronsäure zur Herstellung einer wässrigen Lösung verwendbar als intra-artikulare Reinigungslösung
Przuntek et al. The protective effect of 1-tert. butyl-4, 4-diphenylpiperidine against the nigrostriatal neurodegeneration caused by 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine
AR047480A1 (es) Composicion para la prevencion y/o tratamiento de enfermedades metabolicas oseas; proceso de preparacion y uso de esta composicion
BR9914945A (pt) Processo para proporcionar terapiacosmética/medicinal
Raeburn et al. The effects of alterations in electrogenic Na+/K+‐pumping in guinea‐pig isolated trachealis: their modulation by the epithelium
Morris et al. Regional distribution and kinetics of vinyl acetate hydrolysis in the oral cavity of the rat and mouse
BRPI0407529A (pt) uso de r-10-hidróxi-10,11-dihidro-carbamazepina em dor neuropática

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1913 DE 04/09/2007.